UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?

Breast (Edinburgh), 2022-12, Vol.66, p.49-53

2022

Volltextzugriff (PDF)

Metastasectomy versus radiation of secondary sites in stage IV breast cancer: Analysis from a national cancer registry

Breast (Edinburgh), 2021-12, Vol.60, p.185-191

2021

Volltextzugriff (PDF)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes

Breast (Edinburgh), 2022-08, Vol.64, p.112-120

2022

Volltextzugriff (PDF)

Efficacy of chemotherapy in patients with HR+/HER2–Invasive lobular breast cancer

Cancer treatment and research communications, 2023, Vol.34, p.100666-100666, Article 100666

2023

Volltextzugriff (PDF)

Use of farmers markets by mothers of WIC recipients, Miami-Dade County, Florida, 2011

Preventing chronic disease, 2013-06, Vol.10, p.E95-E95, Article 120178

2013

Volltextzugriff (PDF)

Differential responses to therapy in Hispanic NSCLC patients with EGFR, KRAS, or TP53 mutations

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21027-e21027

2021

Volltextzugriff (PDF)

Prognostic value of systemic inflammatory markers in first- and subsequent-line immunotherapy and durability of response in NSCLC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21210-e21210

2021

Volltextzugriff (PDF)

Abstract P2-12-12: The effect of Neoadjuvant Chemotherapy in reducing the need for axillary lymph node dissection in HR+/HER2- node positive breast cancers

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-12-12

2022

Volltextzugriff (PDF)

Abstract P2-12-17: Comparative outcomes of Neoadjuvant versus Adjuvant chemotherapy in HR+/HER2- node positive breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-12-17

2022

Volltextzugriff (PDF)

Stage migration in breast cancer: Better detection or semantics in staging?

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18800-e18800

2021

Volltextzugriff (PDF)

Metastasectomy versus radiation of secondary sites in stage IV breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1094-1094

2021

Volltextzugriff (PDF)

Cancer disparities among patients with advanced metastatic breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18566-e18566

2021

Volltextzugriff (PDF)

Abstract PD14-06: Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer?

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD14-06-PD14-06

2022

Volltextzugriff (PDF)

Abstract P4-05-10: Composite score combining multi-gene testing with liquid biopsy may have stronger prognostic value in HR+/HER2- breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-05-10

2022

Volltextzugriff (PDF)

Abstract P1-08-33: Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2- breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-08-33

2022

Volltextzugriff (PDF)

Abstract P2-07-07: Does OncotypeDX have predictive value in HER2+ breast cancer?

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-07-07

2022

Volltextzugriff (PDF)

Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15135-e15135

2020

Volltextzugriff (PDF)

Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21547-e21547

2020

Volltextzugriff (PDF)

A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8552-8552

2021

Volltextzugriff (PDF)

Use of brain radiotherapy as part of first course of treatment for NSCLC with de novo brain metastasis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9118-9118

2021

Volltextzugriff (PDF)

Patterns of survival in NSCLC with de novo brain metastasis: SRS, WBRT, and no radiotherapy cohorts

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9122-9122

2021

Volltextzugriff (PDF)

A national analysis of untreated stage III non-small cell lung cancer in black and white patients

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e20561-e20561

2021

Volltextzugriff (PDF)

Social disparities in pain management provision in stage IV lung cancer: A national registry analysis

Medicine (Baltimore), 2023-02, Vol.102 (8), p.e32888

2023

Volltextzugriff (PDF)

Five-year survival stratification using “the Cancer Of the Bladder Risk Assessment” (COBRA) score for micropapillary and sarcomatoid urothelial carcinoma of the bladder variants

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16534-e16534

2022

Volltextzugriff (PDF)

Five-year survival comparison of different treatment modalities for muscle invasive urothelial carcinoma, squamous cell carcinoma and adenocarcinoma of the bladder: An analysis of the National Cancer Database

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.575-575

2022

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(57)
Spanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?

Metastasectomy versus radiation of secondary sites in stage IV breast cancer: Analysis from a national cancer registry

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes

Efficacy of chemotherapy in patients with HR+/HER2–Invasive lobular breast cancer

Use of farmers markets by mothers of WIC recipients, Miami-Dade County, Florida, 2011

Differential responses to therapy in Hispanic NSCLC patients with EGFR, KRAS, or TP53 mutations

Prognostic value of systemic inflammatory markers in first- and subsequent-line immunotherapy and durability of response in NSCLC

Abstract P2-12-12: The effect of Neoadjuvant Chemotherapy in reducing the need for axillary lymph node dissection in HR+/HER2- node positive breast cancers

Abstract P2-12-17: Comparative outcomes of Neoadjuvant versus Adjuvant chemotherapy in HR+/HER2- node positive breast cancer

Stage migration in breast cancer: Better detection or semantics in staging?

Metastasectomy versus radiation of secondary sites in stage IV breast cancer

Cancer disparities among patients with advanced metastatic breast cancer

Abstract PD14-06: Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer?

Abstract P4-05-10: Composite score combining multi-gene testing with liquid biopsy may have stronger prognostic value in HR+/HER2- breast cancer

Abstract P1-08-33: Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2- breast cancer

Abstract P2-07-07: Does OncotypeDX have predictive value in HER2+ breast cancer?

Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer

Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer

A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States

Use of brain radiotherapy as part of first course of treatment for NSCLC with de novo brain metastasis

Patterns of survival in NSCLC with de novo brain metastasis: SRS, WBRT, and no radiotherapy cohorts

A national analysis of untreated stage III non-small cell lung cancer in black and white patients

Social disparities in pain management provision in stage IV lung cancer: A national registry analysis

Five-year survival stratification using “the Cancer Of the Bladder Risk Assessment” (COBRA) score for micropapillary and sarcomatoid urothelial carcinoma of the bladder variants

Five-year survival comparison of different treatment modalities for muscle invasive urothelial carcinoma, squamous cell carcinoma and adenocarcinoma of the bladder: An analysis of the National Cancer Database

Suchergebnisse filtern